The scale of the problem is considerable. Every year, roughly 730,000 new cases of rectal cancer are diagnosed around the globe, making it one of the most common malignancies affecting the digestive tract. For most of modern surgical history, the standard of care has involved radical resection, in which surgeons remove the tumor together with a margin of healthy tissue and the surrounding lymph nodes. The procedure is genuinely effective at curing the cancer, but the anatomical cost is high. The rectum plays a central role in continence and bowel function, and its removal or reconstruction can permanently alter how a person lives. For some patients, particularly those whose tumors sit low in the rectum close to the anal sphincter, a permanent colostomy is an unavoidable consequence.

Professor Toni Seppälä of Tampere University and Tampere University Hospital frames the clinical challenge in terms of a dual mandate. Curing cancer, he emphasizes, is always the primary goal, but the team also wants to preserve the best possible quality of life. If a tumor can be completely eradicated without removing the rectum, a patient may, in the best-case scenario, avoid both major surgery and a stoma. That framing captures the philosophy driving a broader international movement in rectal oncology: the recognition that survival alone is no longer the only meaningful endpoint, and that the functional and psychological toll of radical treatment deserves equal weight in treatment planning.

The new therapy introduced at Tays is known medically as high-dose-rate brachytherapy, or HDR brachytherapy, delivered in a contact configuration. Unlike external beam radiotherapy, in which radiation is generated by a machine positioned outside the body and must travel through healthy tissue to reach its target, contact brachytherapy places the radiation source directly against the tumor. A device is inserted into the rectum and positioned at the tumor surface, allowing clinicians to deliver a very high dose of radiation precisely where it is needed. The treatment utilizes an iridium-192 radiation source, a radioactive isotope commonly employed in brachytherapy applications because it emits energetic gamma rays suitable for destroying cancer cells while permitting rapid dose falloff at a distance.

That physical property, the steep gradient of dose, is the key technical advantage of the method. Because the radiation source sits immediately adjacent to the tumor, the cancer cells receive a devastating dose while the surrounding healthy tissues, including the bowel wall beyond the tumor, the bladder, and nearby nerves and blood vessels, are largely spared. In conventional external radiotherapy, achieving that kind of selectivity is far harder, and dose limits imposed by surrounding organs often constrain how much radiation the tumor itself can safely receive. Contact brachytherapy effectively sidesteps that constraint by shortening the distance between source and target to millimeters, exploiting the inverse relationship between distance and radiation intensity to concentrate therapeutic energy with remarkable precision.

The treatment is not appropriate for every patient with rectal cancer, and the hospital is careful to emphasize that point. Eligibility is assessed by a multidisciplinary team that includes colorectal surgeons, oncologists, radiation oncologists and radiologists. Tumor size, depth of invasion into the bowel wall, location, and the presence or absence of spread to lymph nodes or distant organs all factor into the decision. One particularly important patient group consists of frail and elderly people for whom major rectal cancer surgery may be especially burdensome or may even pose an excessive risk. It is estimated that more than 100 such patients in Finland every year could stand to benefit from an effective alternative to radical resection, a figure that gives a sense of the immediate clinical demand even before broader patient groups are considered.

The introduction of contact brachytherapy at Tays is part of a wider shift in thinking that has transformed rectal cancer treatment over the past several years. International studies have demonstrated that in some patients, the tumor disappears completely following a combination of radiotherapy and anti-cancer medication, a result termed a complete clinical response. In those cases, careful surveillance may be considered as an alternative to immediate surgery. This strategy is known as organ-preserving treatment, or the watch-and-wait approach. Patients are monitored closely with regular endoscopic examinations and imaging so that any residual tumor or local regrowth can be detected early and treated surgically if necessary. For patients who maintain a complete response over the long term, the rectum is preserved, along with continence and quality of life.

Tumor-targeted brachytherapy is designed to push that strategy further by increasing the number of patients who achieve a complete clinical response in the first place. By intensifying the local radiation dose delivered to the tumor, clinicians hope to eradicate more cancers outright and thereby expand the pool of patients who can safely retain their rectum. As Seppälä explains, the goal is not to treat the cancer less intensively, but more precisely. The team wants to identify a treatment that is sufficiently effective for each patient while avoiding treatments and side effects that would yield no additional benefit. In other words, the intensification is aimed at the tumor itself, not at the patient as a whole, which is precisely where the dose-concentrating physics of brachytherapy offers its advantage.

The clinical innovation is embedded in a structured research framework. The new treatment is linked to the NORPPA research programme, coordinated by Tampere University and Tampere University Hospital, which is developing new organ-preserving treatment approaches for rectal cancer. The research network includes hospitals from across Finland and Estonia, creating a multinational cohort infrastructure capable of generating meaningful evidence about outcomes. The next phase, the NORPPA-2 study, is due to begin in 2027 and will investigate the effectiveness of HDR brachytherapy as part of an organ-preserving treatment strategy. The study will examine how effectively tumor eradication can be achieved by intensifying local radiotherapy and, critically, how many patients can avoid major surgery as a result.

The ambitions of the research programme extend beyond radiation alone. If local radiotherapy proves sufficiently effective against the tumor, the researchers will also investigate whether some patients could be treated without chemotherapy, sparing them the substantial systemic side effects associated with cytotoxic drugs. And if the study confirms the effectiveness and safety of the new method, the group of rectal cancer patients offered organ-preserving treatment as an alternative to surgery could expand significantly in the future. For a disease diagnosed three-quarters of a million times each year, the implications are far-reaching. What is emerging in Tampere is a vision of rectal cancer care in which the question is no longer simply how to remove the cancer, but how to destroy it with the least possible collateral damage to the body and the life that continues after treatment. The iridium-192 source inserted through the rectum may look unassuming, but it represents a deliberate rethinking of the trade-offs that have long been accepted as the price of cure.

Subject of Research: High-dose-rate contact brachytherapy as an organ-preserving treatment for rectal cancer

Article Title: Novel radiotherapy may save increasingly many rectal cancer patients from surgery and stoma

Article References: Novel radiotherapy may save increasingly many rectal cancer patients from surgery and stoma. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: rectal cancer, HDR brachytherapy, contact radiotherapy, organ preservation, watch-and-wait, stoma avoidance, iridium-192, Tampere University Hospital, NORPPA study, radiation oncology, multidisciplinary cancer care, quality of life

The study, published in CVIR Oncology as an open-access short communication, enrolled 97 patients with primary or secondary liver malignancies, of whom 74 completed the final analysis. All participants were treated under conscious sedation with analgesia rather than general anesthesia, and all were interviewed systematically about their pain experience at three distinct time points: during catheter placement under CT fluoroscopy, at the time of radiation delivery when the catheters were removed, and later the same evening on the ward. Pain was scored on the standard numeric rating scale from zero, meaning no pain, to ten, meaning maximum pain. The researchers also tracked age, sex, the number of lesions and catheters, prior treatments, tumor volume, tumor location, and complications classified according to Society of Interventional Radiology guidelines.

The technical choreography of the procedure helps explain why the anesthesia question matters so much. Unlike thermal ablation, where a probe is inserted and the tumor is burned or frozen in a single session, CT-guided HDR brachytherapy unfolds in two stages separated by a change of location. First, under CT fluoroscopic guidance, the interventionalist percutaneously places brachytherapy applicators into and around the tumor while the patient receives intravenous midazolam and fentanyl alongside local lidocaine anesthesia at the puncture site. A second physician stands by throughout, monitoring vital signs and titrating medication. Once the catheters are positioned and the planning scan is complete, the puncture sites are sterilely covered and the patient is escorted to a dedicated radiation operating room, where the iridium-192 source delivers its dose. Only after irradiation are the catheters removed, creating a second moment of potential discomfort, and the patient is then observed for roughly an hour before transfer to the regular ward.

The pain data that emerged were strikingly reassuring. At catheter placement, the moment many clinicians would expect to hurt most, 74.5 percent of patients rated their pain as low, in the zero-to-two range, while 19.0 percent reported moderate pain and only 6.5 percent severe pain. At the time of radiation and catheter removal, the picture improved further: 84.0 percent reported low pain, 11.0 percent moderate, and 5.5 percent severe. On the ward afterward, 79.5 percent reported low pain, 16.0 percent moderate, and 4.0 percent severe. The median doses of sedation were modest, 112.5 micrograms of fentanyl and 2 milligrams of midazolam, underscoring how little pharmacological support the procedure actually demands when performed with careful local anesthesia and image guidance.

Two patterns within the data carry practical weight for clinicians. Women reported significantly higher pain at the time of irradiation, with a p-value below 0.001, and the number of treated lesions was associated with significantly higher pain levels at two of the three measured time points, with p below 0.05. No other parameter, including age, tumor volume, tumor location, or the number of prior treatments, showed a significant relationship with pain perception. The authors suggest that these findings point to patient groups, women and those with multiple lesions, who may warrant heightened attention and more aggressive pain management during brachytherapy, rather than a wholesale change in the sedation strategy.

Safety outcomes were equally encouraging. Across three months of follow-up, mild to moderate complications occurred in 23.0 percent of patients, consisting mainly of pain and fever, while no major complications were observed at all. Patient satisfaction, measured on a ten-point scale from complete dissatisfaction to complete satisfaction, was overwhelmingly positive: 98.5 percent of patients scored their experience at seven or higher, and only a single patient recorded the lowest possible score. For a procedure involving the percutaneous puncture of the liver, the placement of multiple catheters, and the delivery of a high radiation dose directly into malignant tissue, a zero rate of major complications in 74 patients is a result that demands attention.

The biological logic of the technique may partly explain why patients tolerate it so well. Unlike radiofrequency or microwave ablation, where heat generation within the liver can be genuinely painful and respiratory movement during the procedure can compromise both safety and effectiveness, the radiation delivered by an HDR iridium-192 source is itself painless. This, the authors note, potentially accounts for the absence of any significant association between tumor location and pain perception in their data. The trade-off is time and logistics: the procedure takes longer than thermal ablation because of the transfer to the radiation room and the delayed catheter removal, and it is precisely this duration and change of setting that makes conscious sedation arguably more practicable than general anesthesia, avoiding the overhead, risks, and resource demands of an anesthesiology team.

The broader context makes the finding timely. Minimally invasive tumor ablation has surged to an all-time high, driven in part by landmark randomized evidence that thermal ablation can match surgical resection for small colorectal liver metastases, and by emerging navigation techniques such as stereotactic puncture that are expanding what image-guided interventions can achieve. Previous work has shown that HDR brachytherapy achieves high rates of local tumor control without strict limitations on tumor size or location, including ablation of large and very large hepatocellular tumors and of lesions with portal vein tumor thrombosis. As the technique moves toward broader adoption, the anesthesia protocol becomes a genuine bottleneck or enabler: if every case requires general anesthesia, throughput is limited and costs rise, whereas a protocol that keeps the patient comfortable while awake can be integrated directly into the clinical routine of an interventional radiology unit.

The study’s authors are candid about its limitations. It was a single-center, monocentric investigation without a comparative arm, and it relied on patient interviews and structured questionnaires, which introduces the possibility of recall bias, since patient-reported data may be influenced by the timing of assessment. The absence of a general anesthesia comparison group means the study cannot definitively settle the ongoing global debate about the optimal anesthesia method for liver ablation, a debate that until now has drawn almost exclusively on hyperthermal ablation procedures rather than brachytherapy. Some studies have even suggested that general anesthesia might offer oncological advantages, although the authors argue that factors such as tumor location and size likely play a more significant role in outcomes than the sedation technique itself.

Even with those caveats, the conclusion is clear and consequential: CT-guided HDR brachytherapy under conscious sedation with analgesia, performed by interventional radiologists themselves, is safe, feasible, and well tolerated, with low subjective pain, near-universal patient satisfaction, and no major complications. Beyond the immediate clinical benefit for patients with liver malignancies, the finding carries a professional significance for the field. Delivering conscious sedation within the interventional radiology unit, without dependence on anesthesiology services, strengthens the specialty’s autonomy and supports its development as an independent clinical discipline. As the number of minimally invasive tumor ablations continues to climb across centers worldwide, this study suggests that the future of precision liver cancer radiation may be one in which patients remain awake, comfortable, and cared for by the same team that guides the catheters, plans the dose, and delivers the cure.

Subject of Research: Feasibility and safety of CT-guided high-dose-rate brachytherapy for liver tumors under conscious sedation with analgesia

Article Title: Feasibility and safety of CT guided high dose rate brachytherapy of liver tumors performed under conscious sedation with analgesia

Article References: Auer, T. A., Erforth, M. Z., Segger, L., Savic, L. J., Fleckenstein, F., Collettini, F., Fehrenbach, U., & Gebauer, B. (2025). Feasibility and safety of CT guided high dose rate brachytherapy of liver tumors performed under conscious sedation with analgesia. CVIR Oncology, 1(1), Article 26. https://doi.org/10.1007/s44343-025-00026-y

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00026-y

Keywords: brachytherapy, liver cancer, interventional radiology, conscious sedation, CT guidance, hepatocellular carcinoma, iridium-192, pain management, tumor ablation, radiation oncology, patient safety, minimally invasive therapy